BMS-986142

BMS-986142 is an oral, small-molecule, reversible inhibitor of Bruton's tyrosine kinase (BTK). It is being developed by Bristol Myers Squibb for the treatment of autoimmune diseases such as rheumatoid arthritis and primary Sjögren's syndrome. The drug acts by selectively inhibiting BTK, a key enzyme involved in B cell receptor signaling and other immune pathways implicated in autoimmunity. Preclinical studies have shown that BMS-986142 blocks antigen receptor-dependent signaling in human B cells, inhibits cytokine production, co-stimulatory molecule expression, proliferation, Fcγ receptor-dependent cytokine production from peripheral blood mononuclear cells, and RANK-L-induced osteoclastogenesis. Clinical trials have evaluated its safety and pharmacokinetics in healthy volunteers as well as its efficacy in patients with rheumatoid arthritis and Sjögren's syndrome[2][3][4][7].